Strong and Sustained Revenue Growth in Core Business and New Launch Countries
Amicus reported 17th consecutive quarter of double-digit revenue growth at CER, driven by Pompe and Fabry disease.
Q2 revenue reached $154.7 million, up 22% YoY, with significant contributions from newly launched countries including Italy, Switzerland, Portugal, Czech Republic, Sweden, and the Netherlands.
The company expects continued growth in these markets and plans to launch in up to 10 new countries in 2025.
Impact of Competitive Landscape and Market Dynamics
A new large competitor has entered the market, causing some market pause and competitive pressure, which Tandem is monitoring closely.
Despite increased competition, Tandem maintains confidence in its leadership in durable pump starts and market growth, emphasizing the large, underpenetrated market opportunity.
The company expects market growth to continue, with room for multiple players, and is focused on maintaining its leadership through innovation and expanded access.
Commercial Transformation and Sales Process Overhaul
The commercial transformation aims to capitalize on large enterprise and IDN opportunities, with a focus on moving from early-stage to later-stage deals.
The company has retooled its sales team to target hospital CNOs and other key decision-makers, emphasizing change management and clinical benefits.
Progress includes a more disciplined approach to sales forecasting, pipeline management, and deal closure, setting the stage for sustained growth.
Dafinchi